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Baculovirus (BV), an enveloped insect virus with a circular double-stranded DNA genome, 
possesses unique characteristics that induce strong innate immune responses in mammalian cells. I 
show that BV administration in BALB/c mice not only provides sterile protection against a 
subsequent Plasmodium berghei sporozoite infection for up to seven days after the injection but also 
eliminates existing liver-stage parasites completely. The elimination of sporozoites by BV was 
superior to that by primaquine, and this effect occurred in a TLR9-independent manner. At 6 h 
post-BV administration, IFN-α and IFN-γ were robustly produced in the serum, and RNA transcripts 
of IFN-stimulated genes were markedly upregulated in the liver compared with control mice. The in 
vivo passive transfer of post-BV-administration serum effectively eliminated liver-stage parasites, 
and IFN-α neutralization abolished this effect, indicating that the BV liver-stage parasite-killing 
mechanism is downstream of the type I IFN signalling pathway. These findings provide evidence that 
BV-induced fast-acting innate immunity completely kills liver-stage parasites and, thus, may lead to 
new malaria drug and vaccine strategies. 
Extended Abstract (1234) 
Introduction: Malaria is a life-threatening disease cause 216 million cases worldwide and 
almost 445,000 deaths every year. Malaria infection is initiated following injection of Plasmodium 
sporozoites injected into the skin during the taking of a blood meal by Anopheles mosquitoes. The 
sporozoites then migrate to the liver and invade hepatocytes. Before clinical symptoms of malaria 
occur during the blood stage of infection, Plasmodium falciparum in the liver develops into 
exoerythrocytic schizonts for 5 to 6 days. Plasmodium vivax and Plasmodium ovale can develop 
dormant liver-stage forms, known as hypnozoites, which cause relapsing blood-stage infections 
months or years after the primary infection. Moreover, the liver-stage development compensates for 
the low numbers of transmitted sporozoites, a major bottleneck of the Plasmodium life cycle. The 
pre-erythrocytic stages are deal targets for both the vaccine interventions and prophylactic drug 
discovery. Therefore, an effective innate immune response raised before or during the liver-stage 
infection could prevent the onset of disease.  
Autographa californica nucleopolyhedrosis virus (AcNPV), a type of Baculovirus (BV), is an 
enveloped insect virus with a circular double-stranded DNA genome, possesses unique 
characteristics to induce strong innate immune responses in various mammalian cells and in mice. 
BV is also widely used in the pharmaceutical industry for the production of recombinant proteins as 
well as for human gene therapy applications. With the outstanding adjuvant properties on maturation 
of DC and activation of NK cells, BV has recently emerged as a new vaccine vector. Our lab 
(Laboratory of Vaccinology and applied Immunology) has developed BV-based malaria vaccines 
effective for all three-parasite stages: pre-erythrocytic stage, asexual blood stage, and sexual stage.  
 
Objective: The overall aim of this thesis was to examine the characteristics features of BV with 
activation of innate immunity. In the long run, I was chasing against the malaria pre-erythrocytic 
stage by exploiting the adjuvant properties of baculoviral vector. I sought to assess whether BV 
possessed more prophylactic and therapeutic effectiveness than CpG and primaquine, respectively. 
For all experiments in which comparisons were made between control and treated mice, all control 
mice developed blood-stage infection within 6 days following the intravenous injection of 1,000 
sporozoites. Once parasites appeared in the blood of a mouse, the animal subsequently died from the 
infection. All mice that survived sporozoite injection successfully prevented blood-stage parasite 
development.  
 
Method: The experiments of my study were designed to assess whether BV-mediated innate 
immunity could protect animals against malaria challenge infection and whether this immunity could 
eliminate existing liver-stage parasites. Group of mice were intramuscularly administered with BV 
and challenged with Plasmodium berghei sporozoites or vice versa. To check the interferon (IFN) 
dependent killing mechanism, serum levels of type-I and II IFN were measured from mice that were 
intramuscularly administered with BV at 6h. I also investigated whether TLR9 plays an important 
role in BV-mediated parasite killing in the liver. To determine whether the serum cytokines act as 
effectors against liver-stage parasites, a serum transfer assay was performed. Next I examined 
whether neutralization of IFN-α or IFN-γ in the sera altered the effect of the sera on liver-stage 
parasites. To assess the effects of exogenous IFN-α and IFN-γ on the elimination of liver-stage 
parasites, direct administration of recombinant IFN-α or recombinant IFN-γ assay was also 
performed. Finally to confirm the involvement of interferon stimulated genes (ISGs), the gene 
expression levels in the livers of mice that had been intramuscularly injected with BES-GL3 were 
measured by quantitative RT-PCR (qRT-PCR). Protective efficacy of heterologous human adenovirus 
serotype 5 (AdHu5)-prime/BV dual expression system (BDES)-boost immunization against 
sporozoite challenge was also tested. 
 
Results: Here I show that the innate immune responses induced by BV not only eliminate 
Plasmodium liver-stage parasites but also elicit sterile protection against Plasmodium sporozoite 
infection through type I interferon (IFN) signaling pathway. Mice had infected with liver-stage 
parasites before 24 h completely prevented blood-stage parasites following single dose of BV 
intramuscular administration, which was much superior to primaquine (PQ), the only drug approved 
to eradicate liver-stage parasites indicating an excellent therapeutic effect as well as the short-term 
prophylactic effect (table 1 and fig.1). 
 
Table 1. Elimination of liver-stage parasites by BV administrationa 
 
Treatmenta Dose (Routeb) 





PBS (i.v.) 24 h 0 (0/12)d  
BV 1 x 107 pfu (i.v.) 24 h 100 (13/13)d 
BV 1 x 107 pfu (i.v.) 42 h 0 (0/3)  
PBS (i.m.) 24 h 0 (0/9)d 
BV 1 x 108 pfu (i.m.) 24 h 100 (7/7)  
BV 1 x 108 pfu (i.m.) 42 h 0 (0/3)e 
PQ (High)c 2 mg (i.p.) 24 h 100 (5/5) 
PQ (Low)c 0.1 mg (i.p.) 24 h 0 (0/5)e 
 
aBALB/c mice were intravenously injected with 1,000 Pb–conGFP sporozoites. After the indicated 
interval, mice were administrated either with BES-GL3 (described as BV) or PQ. Parasitemia was 
monitored on days 5-8, 11, and 14 after sporozoite injection. Once parasites appeared in the blood, all 
mice died. 
bi.v., intravenous; i.m., intramuscular; i.p., intraperitoneal. 
cThe two different doses of PQ were administrated to eliminate liver-stage parasites. The two different 
doses of PQ as High (2 mg/100 µl) and Low (0.1 mg/100 µl) were administrated to eliminate 
liver-stage parasites. 
dCumulative data from three experiments. 











Figure 1: Effect of BV intramuscular administration on liver-stage parasites (A, B). 
Mice were challenged by infection with Pb-Luc sporozoites at 0 h, followed by 
intramuscular administration of BES-GL3 (108 pfu; described as BV) at the indicated 
timepoints. Luminescence in the liver indicates parasite growth, whereas that in the 
thigh shows the transgene expression by intramuscular BV injection. The heatmap 
visible in each mouse image represents the total flux of photons (p/s/cm2) in that area. 
Rainbow scales are expressed in radiance (p/s/cm2/sr). 
 At 6 h post-BV administration, IFN-α and IFN-γ were robustly produced in the sera, and 
RNA transcripts of interferon-stimulated genes were drastically upregulated in the liver compared 
with control mice (fig. 2).  
 
 
BV possesses unique characteristics that activate DC-mediated innate immunity through 
MyD88/TLR9-dependent and -independent pathways. Therefore, next I investigated whether TLR9 
plays an important role in BV-mediated parasite killing in the liver. A single dose of intramuscularly 
administered BES-GL3 completely prevented blood-stage parasites in all TLR9-/- mice that had been 
previously infected with liver-stage parasites. In contrast, no elimination effect or parasitemia delay 












Fig. 2: BV intramuscular administration BV administration rapidly induces type I 
and II IFNs in sera. (A-B) Levels of IFN-α (A) and IFN-γ (B) in sera from WT or 
TLR9-/- mice at 6 h after intramuscular administration of BES-GL3 (described as BV) 
(108 pfu), CpG, or PBS (n = 9-10). Bars show means ± SD. The difference from the PBS 
group was assessed by a Kruskal-Wallis test with Dunn’s correction. **p < 0.01, ****p 
< 0.0001. 











PBS TLR9-/- - 24 h 0 (0/7) 
BV TLR9-/- 1 x 108 pfu 24 h 100 (7/7) 
BV WT 1 x 108 pfu 24 h 100 (5/5) 
CpG WT 50 µg 6 h 100 (5/5) 
CpG WT 50 µg 24 h 0 (0/4)b 
CpG TLR9-/- 50 µg 24 h 0 (0/5) 
 
aTLR9-/- (BALB/c background) or WT mice were intravenously injected with 1,000 Pb-conGFP 
sporozoites. After 24 h, mice were intramuscularly administrated either with BES-GL3 (described as 
BV) or CpG ODN 1826 (described as CpG). Parasitemia was monitored on days 5-8, 11, and 14 after 
sporozoite injection. Once parasites appeared in the blood, all mice died. 
bSignificant delay of parasitemia was observed in infected mice, compared with the PBS. 
 
The in vivo passive transfer with sera from mice intramuscularly administered with BV 
effectively eliminated liver-stage parasites and this effect was canceled by neutralization of IFN-α 
but not IFN-γ in the sera, indicating a killing mechanism downstream of type I IFN signaling 







Conclusion: Collectively these results demonstrate that BV administration has both therapeutic 
and prophylactic immunostimulatory effects. Thus, this study provides great potentials of BV for 
development of a new IFN-inducing non-haemolytic single-dose alternative to PQ. We propose that 
these findings serve to inform us a new insight into the development of an effective vaccine platform 









Fig. 3: IFN-α induced by BV intramuscular administration contributes to 
elimination of liver-stage parasites. Results of a serum transfer assay to determine the 
role of IFN-α and IFN-γ in the elimination of liver-stage parasites. Sera collected from 
mice at 6 h after BV administration was neutralized by either anti-IFN-α or anti-IFN-γ 
antibody. Passive transfer of antibody-treated sera, non-treated sera, or PBS was 
conducted at 24 h after sporozoite infection (n = 5). The difference from the PBS group 
was assessed by a Kruskal-Wallis test with Dunn’s correction. *p < 0.05, ***p < 0.001.  
 
審査結果の要旨 
三日熱マラリア原虫は、急性期（赤内期）にアルテミシニンによる治療で症状が改善するが、
肝細胞中に原虫の休眠体（ヒプノゾイト）が残存し、数カ月～数カ年の期間を経て 80%が
再発する。このマラリア再発は、マラリアの撲滅にとっての大きな障害となっている。ヒプ
ノゾイトを排除できる唯一の薬剤であるプリマキンは、(i) G6PD欠損の人に投薬すると溶
血性貧血を引き起こし死に至る場合がある。(ii)プリマキンによる根治療法(14日間)を行っ
ても時に再発が見られ、プリマキン低感受性原虫の存在が懸念されている。このような禁忌、
副作用、耐性原虫出現等々の問題点があり使用が制限されている。プリマキンに替わる薬剤
の探索が長年続けられてきているが開発には至っていない。本論文はバキュロウイルス(BV)
が誘導するユニークな自然免疫応答に着目し、ネズミマラリア原虫をモデルとして「BVを
大腿部に筋注すると遠距離にある肝臓内のマラリア原虫に対して 100%の強力な殺傷効果
を発揮する」ことを見出した。BV接種により誘導された IFN-a, -gが肝臓に作用し、その結
果各種 IFN-stimulated gene群が活性化して肝臓内マラリア原虫を殺傷することを明らかに
した。全く新規の「自然免疫賦活化薬」という新しいコンセプトでプリマキンを凌駕する抗
マラリア新薬の開発を提案している。本審査委員会は、研究成果の新規性および口頭発表会
における学位申請者の発表と討論の能力を考慮して、当該学位論文は博士（学術）に値する
と判定した。
